SUSPECT ADVERSE REACTION REPORT														CIC	ЭM	IS F	OI	RM
PARENTINIMALS   Its COUNTRY   2. DATE OF SIMTH   29 AGE   3.5EX   3. WEIGHT   4. REPORTATION   1. REPORTAT																		
1.6PITENT INTERIALS   To COUNTRY   2.0PITENT   2.0PITENT   1.0PITENT   2.0PITENT   2.0PI	SUSPECT ADVERSE REACTION REPORT																	
1.6PITENT INTERIALS   To COUNTRY   2.0PITENT   2.0PITENT   1.0PITENT   2.0PITENT   2.0PI	SOUL EST ADVENSE REACTION REPORT						1			Т	1		П		Т	Т	Ι	I
International   Internationa								$\square$										
## TO DESCRIBE FEACHTONS) producting relevant treatable data			ı	. REACTIO	ON INFOR	MATION												
Unk Vears Male  7. 11 SESCRES BEACTONS) into valong recover training designs and state of the common state	(first, last)			T							_	-12				го		
Continued on Additional Information Page Report Page   Manual American   Page Report Page	UNKNOWN 1	PANAMA   L		1 0		Unk	ay			rea			ADV	ERSE R	(EAC	TION		
Grade IV anemia [Anaemia]  Case Description: Additional information: It was reported that during a virtual interaction with oncologist Dr. PRIVACY on 30May/S at a paproximately 8:00 a.m., the use of the combination of Talazoparib with Enzalutamide was mentioned in the case of an 80-year-old male patient with advanced metastatic castration-resistant prostate cancer. The doctor stated that the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient died from the cancer.  II. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  15. DAILY DORRISS   11. DAILY SUSPECT DRUG(S) INFORMATION  16. DAILY DORRISS   17. DAILY SUSPECT DRUG(S) INFORMATION  17. DAILY DORRISS   17. DAILY SUSPECT DRUG(S) INFORMATION  18. DAILY DORRISS   17. DAILY SUSPECT DRUG(S) INFORMATION  19. DAILY SUSPECT DR	7 + 13 DESCRIBE REACTION( Event Verbatim [PREFERRED	S) (including relevant tes	sts/lab data) ns if any separated	by commas)								Ø	PAT	IENT DIE	ΞD			
Case Description: Additional Information: It was reported that during a virtual interaction with encologist Dr. PRIVACY on 30May/25 at approximately 8:00 a. m., the use of the combination of Talazoparib With Enzalutamide was mentioned in the case of an 80-year-old male patient with advanced metastatic castration-resistant prostate cancer. The doctor stated that the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient developed grade IV anemia, which required multiple transfusions.  It is usered provided grade IV anemia, which required multiple transfusion and the fatal transfusion and transfusions. It is usered to patient developed grade IV anemia, which required multiple transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient developed grade IV anemia and transfusions. It is usered to patient de	grade IV anemia [Ana	emia]				INVOLVED OR						NT						
Enzalutamide was mentioned in the case of an 80-year-old male patient with advanced metastatic castration-resistant prostate cancer. The doctor stated that the patient developed grade IV anamia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient did from the cancer.    II. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) InFORMATION  15. DID REACTION (Continued on Additional Information Page)  16. DAILY DOSE(S)  17. NOICATION(S) FOR USE  17. OUTCOM (Continued on Additional Information Page)  18. DID REACTION  19. D					•			_	ist Dr	r.								
castration-resistant prostate cancer. The doctor stated that the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the outcome was fatal, as the patient died from the cancer.    II. SUSPECT DRUG(S) INFORMATION	Enzalutamide was me	entioned in the ca	se of an 80-y	ear-old male	patient with	advanced meta	asta	tic					INVO	OLVED F	PERS	SISTE T	NT	
II. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  17. Talazopario (TALAZOPARIB) Unknown  18. DADAY DOSE(S)  18. DADAY DOSE(S)  19. TARAZILIAMIDE) Unknown  19. TARAZILIAMIDE) Unknown  19. TARAZILIAMIDE (ENZALUTAMIDE) Unknown  19. TARAZILIAMIDE) Unknown  19. TARAZILIAMIDE (ENZALUTAMIDE) Unknown  10. TARAZILIAMI Unknown  10. TARAZILIAMI Unknown  11. TARAZILIAMI Unknown  11. TARAZILIAMI Unknown  12. TARAZILIAMI Unknown  11. TARAZILIAMI Unknown  11. TARAZILIAMI Unknown  11. TARAZILIAMI Unknown  11. TARAZILIAMI Unknown  12. TARAZILIAMI Unknown  11. TARAZILIAMI													DISA	ABILITY	OR			
II. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  17. Talazopario (TALAZOPARIB) Unknown  18. DADY DOSE(S)  18. DADY DOSE(S)  19. DE RACTION ADMITTER STOPPING  19. DADY DOSE(S)  19. Unknown  22. Unknown  22. Unknown  23. OTHER RELEVANT HISTORY. (e.g. diagnostics alwayes, pagnancy with last month of period, etc.) Type of History / Notes  19. Description  10. MANUFACTURER INFORMATION  26. REMARKS  26. REMARKS  26. REMARKS  27. DATES INFORMATION  26. REMARKS  28. REMARKS  28. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
14. SUSPECT DRUG(S) (mobile genetic nume) #1) Talazoparito (TALAZOPARIB) Unknown #2   Enzalutamide (ENZALUTAMIDE) Unknown #1   Makarta Affir Stopping (Continued on Additional Information Page) #1   Subut Dose(s) #1   Unknown #2   Unknown #2   Unknown #2   Unknown #2   Unknown #2   Unknown #2   Unknown #3   Unknown #4   Outlined on Additional Information Page) #4   Advanced metastatic castration-resistan #2   Unknown #3   Unknown #4   Unknown #5   Unknown #6   Unknown #6   Unknown #7   Unknown #7   Unknown #7   Unknown #8   Unknown #8   Unknown #8   Unknown #8   Unknown #9   Unknown #9   Unknown #1   Unknown #1   Unknown #2   Unknown #2   Unknown #4   Unknown #5   Unknown #6   Unknown #6   Unknown #7   Unknown #7   Unknown #7   Unknown #8   Unknown													LIFE	REATENI	NG			
### 1) Talazoparib (TALAZOPARIB) Unknown ### 2) Enzalutamide (ENZALUTAMIDE) Unknown ### 2) Enzalutamide (ENZALUTAMIDE) Unknown ### 10 AMIN' DSE(s) ### 1) Unknown ### 1) Unknown ### 10 Unknown ### 1) Unknown ### 2) Unknown ### 10 Unknown ### 2) Unknown ### 10 Unknown ### 10 Unknown ### 2) Unknown ### 10 Unknown ### 2) Unknown ### 2) Unknown ### 2) Unknown ### 2) Unknown ### 3 AMIN AMIN AMIN AMIN AMIN AMIN AMIN AMIN			II. SU	SPECT DI	RUG(S) IN	IFORMATIO	N											
#2 ) Enzalutamide (ENZALUTAMIDE) Unknown  (Continued on Additional Information Page)  15. DAILY DOSE(S) #1 ) MERCUTE(S) OF ADMINISTRATION #2 ) Unknown    Tr. INDICATION(S) FOR USE #1 ) advanced metastatic castration-resistan   Continued on Additional Information Page)   Tr. INDICATION(S) FOR USE #1 ) JUNKNOWN   Tr. INDICATION(S) FOR USE #1 ) Unknown   Tr. INDICATION(S) FOR USE #1 ) JUNKNOWN   Tr. INDICATION(S) FOR USE #1 ) JUNKNOWN   Tr. INDICATION FOR USE   Tr. INDICATION FOR USE #1 ) JUNKNOWN   Tr. INDICATION FOR USE   T			wn		, ,						20	AB	BATE A	ACTION AFTER S	STOF	PPING		
#1 ) Unknown   #2 ) Unknown   #2 ) Unknown   #2 ) Unknown   #3 ) Unknown   #4 ) Unknown   U		,			(Cont	inued on Addition	nal Ir	nforma	ation F	Pag	e)	DR	.UG?					
17. INDICATIONIS) FOR USE #1 ) advanced metastatic castration-resistan #2 ) Unknown #3. THERAPY DATES(from/to) #1 ) Unknown #1 ) Unknown #1 ) Unknown #1 ) Unknown #2 ) Unknown #2 ) Unknown #2 ) Unknown #3. THERAPY DATES(from/to) #4   Yes   NA    Ves   NA							ON						YES	s 🔲 N	0	<b>X</b> N	A	
### ) advanced metastatic castration-resistan #### (Continued on Additional Information Page)  18. THERAPY DATES(from(n)) ## 1) Unknown ## 2) Unknown ## 2) Unknown  ## 2) Unknown  ## 2) Unknown  ## 2) Unknown  ## 3) Unknown  ## 3) Unknown  ## 3) Unknown  ## 4) Unknown  ## 4) Unknown  ## 5) Unknown  ## 5) Unknown  ## 5) Unknown  ## 6) Unknown  ## 6) Unknown  ## 7) Unknown  ## 7) Unknown  ## 8) Unknown  ## 9) Unknown  ## 8)					#2 ) Unkn	own					2.	1. DIE	) REA	CTION				
18. THERAPY DATES (from/to) #1 ) Unknown #2 ) Unknown #2 ) Unknown #3 ) Unknown #4 ) Unknown #4 ) Unknown #4 ) Unknown #4 ) Unknown #5 ) Unknown #5 ) Unknown    III. CONCOMITANT DRUG(S) AND HISTORY    Concomitant Drug(S) AND Dates of Administration (exclude those used to treat reaction)    Concomitant Drug(S) AND Dates of Administration (exclude those used to treat reaction)   Concomitant Drug(S) AND Dates of Administration (exclude those used to treat reaction)   Concomitant Drug(S) AND HISTORY   Concomitant D	#1 ) advanced metasta	tic castration-resis	tan		(Cont	inued on Addition	nal Ir	nforma	ation F	Pag		RE	APPE	EAR AFT		•		
#2 ) Unknown  #2 ) Unknown  #2 ) Unknown  #2 ) Unknown	18. THERAPY DATES(from/to)				19. THERAPY	D. THERAPY DURATION												
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)  23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Plizer Inc Head Drug Safety Surveillance Plizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  PV202500066000  PV202500066000  PV30 AME AND ADDRESS OF REPORTER NAME AND ADDRESS OF REPORTER NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	1 '											] '	, LJ."		Δ'''	1		
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)  23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Plizer Inc Head Drug Safety Surveillance Plizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  PV202500066000  PV202500066000  PV30 AME AND ADDRESS OF REPORTER NAME AND ADDRESS OF REPORTER NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.			III. CON	COMITAN	Γ DRUG(S	S) AND HIST	OR	RΥ										
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  PV202500066000  Description  IV. MANUFACTURER INFORMATION  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	22. CONCOMITANT DRUG(S)	AND DATES OF ADMINI	STRATION (exclud	de those used to tre	eat reaction)													
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  PV202500066000  Description  IV. MANUFACTURER INFORMATION  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  PV202500066000  Description  IV. MANUFACTURER INFORMATION  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  PV202500066000  Description  IV. MANUFACTURER INFORMATION  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
Unknown  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  PV202500066000  IV. MANUFACTURER INFORMATION  26. REMARKS  26b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.		RY. (e.g. diagnostics, alle																
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  25b. NAME AND ADDRESS WITHHELD.			Type of History	y / Notes	Description													
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  25b. NAME AND ADDRESS WITHHELD.																		
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b. MFR CONTROL NO. PV202500066000  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
Pfizer Inc Head Drug Safety Surveillance Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b, MFR CONTROL NO. PV202500066000  25b. NAME AND ADDRESS WITHHELD.																		
Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES Phone: 212 733 5544  24b, MFR CONTROL NO. PV202500066000  25b. NAME AND ADDRESS WITHHELD.	Pfizer Inc				20. RE	WARNS												
Phone: 212 733 5544  24b, MFR CONTROL NO.  PV202500066000  25b. NAME AND ADDRESS OF REPORTER  NAME AND ADDRESS WITHHELD.	Pfizer, Inc. 66 Hudson Boulevard East New York, New York 10001 UNITED STATES																	
PV202500066000 NAME AND ADDRESS WITHHELD.			-															
PV202500066000		24b. MFR CONT	ROL NO.		25b. N	AME AND ADDRESS (	OF RE	EPORT	ER						_			
		PV2025000	066000		NAM	E AND ADDRES	SS W	/ITHH	IELD.									
24c. DATE RECEIVED 24d. REPORT SOURCE STUDY LITERATURE	24c. DATE RECEIVED BY MANUFACTURER	I		RATURE														
30-MAY-2025	30-MAY-2025		ш															
DATE OF THIS REPORT 25a. REPORT TYPE 03-JUN-2025 INITIAL FOLLOWUP:		25a. REPORT TY	/PE															

## ADDITIONAL INFORMATION

14-19.	SUSPECT	DRUG(S)	continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1 ) Talazoparib (TALAZOPARIB) Unknown;	; Unknown	advanced metastatic	Unknown;
Regimen #1		castration-resistant prostate	Unknown
		cancer (Hormone-refractory	
		prostate cancer)	